The new, longevity industry focused website, Longevity Technology is running an interview with our Founder/Director Attila Csordas, called Proteomics and biological age measurement. The quotes below are from the original, much more detailed version of the interview.

Longevity Technology: What is your current funding situation?

Attila Csordas: We are about to close our first serious funding round. Now is a good time to join the team.

Longevity Technology: Genetic testing is an increasingly crowded space – how do you set yourself apart from other companies in this area?

Attila Csordas: How about not doing genetics at all in the first place? It’s static, it talks about potential disease risks, frequently diseases you cannot treat, it can be a scary information to digest. In striking contrast with the practice of personal genetic testing, AgeCurve’s focus is on biological aging, and it is not a disease in the clinical sense, yet it is the biggest risk factor of chronic age-associated diseases. Biological aging is something that happens with everybody. I am having it, you are having it, and it does not get any better with time. Additionally, biological aging is really ‘agings underneath’, the results of many separate processes mainly governed by changing protein functions. Hence, the AgeCurve experience starts with protein based aging scores, not health scares, as genetic tests do. What this all means is that we do proteomics and we are the only ones doing so in a direct-to-consumer setting and focusing on capturing the dynamics that is essential in understanding biological aging.

Longevity TechnologyHow does AgeCurve work?

Attila Csordas: At AgeCurve, we quantify thousands of proteins in saliva and select the ones showing relevant patterns to build biological aging scores, amongst others. Based on non-invasive saliva collection (the emerging standard of direct-to-consumer omics profiling), the sample is sent to our partner lab for the mass spec runs and the results are delivered to our users a couple of weeks later as a native web application accessible with digital devices.

We already capture bits and pieces of the majority of the nine molecular hallmark processes of aging with many customised protein stories: proteostasis, senescence cells, innate immunity – inflammaging, cellular energy/respiration. And we are adding more stories since we have thousands of sequenced/measured human proteins. This comprehensiveness is unprecedented on the market.

Although aging is not a disease, clinically speaking, we have started to work with clinicians on separate continents to see how our high-throughput protein measurements and aging-focused computational resources can provide clinically actionable information.


Comments are closed